Grail Catapults 30%-Plus As FDA Mulls Cancer-Detecting Blood Test

Live updates

1. 1h ago

   Grail Shares Surge as FDA Staff Report No Major Concerns for Galleri Test

   Grail stock rose more than 30% following the release of FDA briefing documents that showed a positive evaluation of its Galleri multi-cancer blood test. FDA staff indicated they have no major concerns regarding the test, which is designed to detect cancer in healthy individuals. This rally marks the company's best trading day in over 1.5 years. The positive internal review comes just as the FDA prepares for an advisory committee meeting to evaluate the test's efficacy and regulatory approval path.

   Why it matters

   The Galleri test aims to identify multiple types of cancer through a single blood draw before symptoms appear. Regulatory approval from the FDA is required for the test to be marketed as a diagnostic tool for the general population. A positive outcome from the advisory committee could significantly expand the company's market reach.

   What is confirmed

   • Grail stock increased by more than 30%.
   • FDA staff reported no major concerns regarding the multi-cancer test.
   • The Galleri test is designed to detect signs of multiple cancers in healthy people.
   • Grail experienced its best trading day in more than 1.5 years.

   What to watch next

   • The outcome of the FDA advisory committee vote on the Galleri test.
   • Official FDA decision on regulatory approval for the blood test.
   Sources used for this update (8)

   1. Investor's Business Daily — Grail Catapults 30%-Plus As FDA Mulls Cancer-Detecting Blood Test
   2. Reuters — Grail rallies as FDA staff flags no major concerns for multi-cancer test
   3. Yahoo Finance — GRAL Stock Clocks Best Day In Over 1.5 Years — FDA Papers Lift Galleri Approval Hopes
   4. Endpoints News — FDA offers little comment on Grail cancer test ahead of adcomm
   5. Seeking Alpha — GRAIL surges as FDA briefing doc shows positive evaluation of Galleri cancer test
   6. WSJ — Opinion | A Grail Cancer Test for the FDA
   7. STAT — What a vote on Grail’s cancer detection test could mean for the company, patients, and regulators
   8. medicalxpress.com — Grail's cancer blood test faces high-stakes FDA review
   confidence 95%